MEI Pharma, Inc.

États‑Unis d’Amérique

 
Quantité totale PI 63
Rang # Quantité totale PI 21 470
Note d'activité PI 2,6/5.0    48
Rang # Activité PI 15 303
Symbole boursier
ISIN US55279B2025
Capitalisation 18.70M  (USD)
Industrie Drug Manufacturers - Specialty & Generic
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

18 1
18 0
24 0
2
 
Dernier brevet 2024 - Combination of a cdk inhibitor a...
Premier brevet 2004 - Benzimidazole derivates: prepara...
Dernière marque 2021 - ZANOVERSE
Première marque 2012 - MEI PHARMA

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 Invention Combination of a cdk inhibitor and a flt3 inhibitor for the treatment of cancer. The disclosure h...
2023 Invention Combination therapies. Provided herein are methods of treating and sensitizing cancer comprising ...
Invention Combination therapy of pi3k inhibitor and pd-1 inhibitor. Provided herein are methods of treating...
Invention Isoflavonoid compounds and methods for the treatment of cancer. Provided herein is a pharmaceuti...
2022 Invention (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimi...
Invention Combination therapy. Provided herein are methods of treating diseases, such as cancer, using a c...
Invention Voruciclib dosing regimens and methods of treatment including the same. The present disclosure r...
Invention Voruciclib dosing regimens and methods of treatment including the same. The present disclosure re...
Invention Combination therapy. Provided herein are methods of treating diseases, such as cancer, using a co...
2021 Invention Treatment of kras mutant cancers. The disclosure herein provides combination therapies for the t...
Invention Treatment of kras mutant cancers. The disclosure herein provides combination therapies for the tr...
P/S pharmaceutical products for the treatment of cancer and immune-related diseases and disorders; ph...
Invention Combination therapies. Provided herein are compositions, methods, and kits for treating cancer co...
Invention Preparation of a 1,3,5-triazinyl benzimidazole. Described herein is the preparation of a 1,3,5-t...
Invention Preparation of a 1,3,5-triazinyl benzimidazole. Described herein is the preparation of a 1,3,5-tr...
2020 Invention Combination therapies. Provided herein are methods of treating and sensitizing cancer comprising...
Invention Voruciclib polymorphs and methods of making and using thereof. The disclosure relates to crystal...
Invention Voruciclib poly morphs and methods of making and using thereof. The disclosure relates to crystal...
Invention Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ethyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylam...
2019 Invention Combination therapies for high and very high risk mds. Provided herein are methods of treating h...
Invention Combination therapies for high and very high risk mds. Provided herein are methods of treating hi...
Invention Treatment of b cell malignancies. Provided herein are methods of treating cancer using a phospho...
Invention Treatment of relapsed follicular lymphoma. Provided herein are methods treating follicular lymph...
Invention Treatment of relapsed follicular lymphoma. Provided herein are methods treating follicular lympho...
Invention Treatment of b cell malignancies. Provided herein are methods of treating cancer using a phosphoi...
2018 Invention Benzimidazole derivatives: preparation and pharmaceutical applications. The present invention rel...
2017 Invention Polymorphic forms of 3-[(2-butyl-1-(2-diethylamino-ethyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acryla...
2012 P/S Pharmaceuticals for use in the treatment of oncological disorders, neurological disorders, and im...